Plasma Derived Therapy Market Regional Analysis:
North American Market Insights
In plasma derived therapy market, North America industry is expected to hold largest revenue share of 44% by 2035. The market growth in the region is also expected on account of the latest initiatives that are taken by the government and private bodies to encourage the therapeutic system that has helped the market to achieve new heights.
Moreover, the growing number of plasma collection units in this sector has emerged as a major factor that has boosted the plasma derived therapy market. As per the recent report, around 2,215,000 units (95% confidence interval (CI, 2,084,000–2,347,000 units) of plasma were transfused in the region. in 2021 resulting in an increase of 1.4% from 2019 when 2,185,000 plasma units were transfused. Additionally, with the growing frequency of chronic diseases risk of chronic wounds is increasing leading to the growing demand for cold plasma for treatment.
The significant demand for plasma in the United States has strengthened the growth potential for key market players in the region for the growth of plasma-derived therapy. According to The American National Red Cross, around 5,000 units of platelets and 6.500 units of plasma are required on a daily basis in the U.S.
The growing frequency of autoimmune disorders in Canada has led to the marked growth of plasma-derived therapy as it is one of the most effective in treating such disorders. According to the latest report, females have a higher frequency of autoimmune diseases (60.6% vs 34.4%, p<0.001) in the region. Additionally, around 4% of the world's population is affected by one of more than 80 different autoimmune diseases.
APAC Market Insights
The Asia Pacific region will also encounter huge growth for the plasma derived therapy market during the forecast period and will hold the second position owing to the profitable opportunities in novel plasma therapy production. Additionally, the hospital sector is recording rapid growth due to advanced healthcare reforms, and a notable rise in accidents across the region led to the market growth of plasma-derived market growth.
According to WHO, 28% of global road traffic deaths occurred in the Southeast Asia Region. With more than 2 deaths occurring per minute and over 3200 per day, road traffic crashes remain the leading killer of children and youth aged 5–29 years. With the increasing number of accident cases, the demand for plasma is increasing parallelly.
China has made major contributions to the growth of the plasma market in the Asia-Pacific region and the use of plasma in many therapeutic treatments is now widely accepted by the population for the treatment of various diseases. China offers profitable opportunities ahead in the production of novel plasma therapies. As per the latest report, China has given plasma therapy to around 250 patients out of which 91 cases have shown improvement in symptoms and clinical indicators.
Increasing cases of peripheral nerve injury (PNI) in Japan are driving the market growth of plasma-derived therapies. Platelets-rich protein (PRP) therapy is introduced to the patients by integrating the latest technologies for repairing and rejuvenating the tissues damaged due to injury or chronic diseases.
